MVT-401

About Microvascular Therapeutics

Microvascular Therapeutics is a clinical-stage biotech company leveraging a proprietary microbubble and nanobubble platform to transform ultrasound from a diagnostic imaging tool into a therapeutic modality. Its diversified pipeline targets significant unmet needs in cardiology, oncology, neurology, and ophthalmology, with its lead program, MVT-100, having completed Phase II trials. The company is led by a founder with a proven track record in ultrasound contrast agent development and commercialization, and it is advancing its programs through strategic partnerships and non-dilutive grant funding.

Therapeutic Areas